{
    "2020-04-28": [
        [
            {
                "time": "",
                "original_text": "泰格医药(300347.SZ)一季度净利润升75.22%至2.55亿元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "一季度",
                        "净利润",
                        "增长",
                        "75.22%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "泰格医药：一季度净利润同比增长75.22%",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "一季度",
                        "净利润",
                        "同比增长",
                        "75.22%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "现金流充裕，泰格医药为何还选择“A+H”模式上市？",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "A+H模式",
                        "上市",
                        "现金流"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|点评】泰格医药: 疫情影响短期业绩，看好Q2-Q3逐步恢复趋势",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "疫情",
                        "短期业绩",
                        "Q2-Q3",
                        "恢复趋势"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}